|Articles|January 5, 2022

COVID-19 Vaccination Does Not Increase Risk of Preterm Birth

Author(s)Nina Cosdon

The CDC recommends all pregnant women receive a COVID-19 vaccine, finding vaccination does not increase risk of preterm birth or small-for-gestational-age at birth.

Yesterday, the US Centers for Disease Control and Prevention (CDC) reported that COVID-19 vaccination has no correlation with preterm birth or small-for-gestational-age at birth.

COVID-19 vaccines have been recommended during pregnancy to prevent severe maternal and birth infection outcomes. Pregnant women are at increased risk of severe or fatal COVID-19 infection, and are more likely to need ICU admission, invasive ventilation, and machine-assisted blood oxygenation than nonpregnant people.

However, vaccination rates among pregnant women have been low, largely due to concerns that the vaccine could cause adverse effects in the mothers or their babies.

Prior studies of maternal COVID-19 vaccination and birth outcomes have been hindered by small sample sizes or a lack of an unvaccinated control group. A CDC-sponsored study evaluated risk of preterm birth and small-for-gestational-age (SGA) at birth after maternal COVID-19 vaccination.

The retrospective cohort study, published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), utilized data from 8 Vaccine Safety Datalink (VSD) health organizations.

“Preterm birth” was defined as fewer than 37 weeks of gestation, and “SGA at birth” was defined as a birthweight less than the tenth percentile for gestational age.

The study included 46079 pregnant women with live births, 10064 (21.8%) of whom received one or more COVID-19 vaccine doses during their pregnancy and between December 15, 2020-July 22, 2021.

Almost all women (98.3%) were vaccinated during their second or third trimester. Up to 96% of the vaccinated mothers received an mRNA Pfizer-BioNTech or Moderna vaccine.

The investigators found that COVID-19 vaccination during pregnancy was not associated with preterm birth (adjusted hazard ratio [aHR] = 0.91; 95% CI = 0.82–1.01). Vaccination during pregnancy was also not associated with SGA at birth (aHR = 0.95; 95% CI = 0.87–1.03).

Notably, there was no increased risk when stratified by mRNA COVID-19 vaccine type, or by second or third trimester vaccination, as compared with risk among the unvaccinated pregnant cohort.

The CDC reified their recommendation that women who are pregnant, were recently pregnant and/or lactating, or are trying to become pregnant all receive a full COVID-19 vaccine regimen.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.